Primary Malignant Melanoma of the Female Urethra

Urology

Volumn 70, Issue 6, 2007, Pages 1222.e13-1222.e16

  Yoshizawa, Tsuyoshi ^a   Kawata, Nozomu ^a   Sato, Katsuhiko ^a   Hirakata, Hitoshi ^a   Igarashi, Takumi ^a   Ichinose, Taketo ^a   Yamaguchi, Kenya ^a   Takahashi, Satoru ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; DACARBAZINE; NIMUSTINE; VINCRISTINE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; FEMALE; HUMAN; MELANOMA; PRIORITY JOURNAL; TUMOR VOLUME; URETEROSTOMY; URETHRA DISEASE;

EID: 37349091596     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.09.008     Document Type: Article

References (10)

1. Kim C.J., Pak K., Hamaguchi A., et al. Primary malignant melanoma of the female urethra. Cancer 71 (1993) 448-451
2. Oliva E., Quinn T.R., Amin M.B., et al. Primary malignant melanoma of the urethra: a clinicopathologic analysis of 15 cases. Am J Surg Pathol 24 (2000) 785-796
3. Agrup G., Agrup P., Andersson T., et al. 5 years experience of 5-S-cysteinyldopa in melanoma diagnosis. Acta Derm Venereol 59 (1979) 381-388
4. Yamamoto A., and Ishihara K. Clinical study of DAV + IFNβ therapy for malignant melanoma. Int J Immunother 7 (1996) 73-78
5. Nissenkorn I., Servadio C., Avidor I., et al. Malignant melanomas of female urethra. Urology 24 (1987) 562-565
6. DiMarco D.S., DiMarco C.S., Zincke H., et al. Outcome of surgical treatment for primary malignant melanoma of the female urethra. J Urol 171 (2004) 765-767
7. Wagner J.D., Gordon M.S., Chuang T.Y., et al. Current therapy of cutaneous melanoma. Plast Reconstr Surg 105 (2000) 1774-1799
8. McClay E.F., and McClay M.E. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 23 (1996) 744-753
9. Moschos S.J., Edington H.D., Land S.R., et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24 (2006) 3164-3171
10. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 95 (2006) 581-586